For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab (Imfinzi; AstraZeneca) and chemotherapy both before and after surgery were ...

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...

Durvalumab is an IV drug that boosts the immune system’s ability to detect and kill cancer cells. It’s used to treat a range ...

Adding perioperative durvalumab (Imfinzi) to FLOT chemotherapy significantly improved event-free survival (EFS) compared with ...

Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain high.

Addition of perioperative durvalumab to standard chemotherapy improved outcomes for locally advanced gastric cancers. Durvalumab did not delay surgery or adjuvant treatment. CHICAGO — Adding ...

Adding the immune checkpoint inhibitor durvalumab (Imfinzi) to the standard chemotherapy regimen of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) improved event-free survival (EFS ...

An analysis of the CALLA study shows that ctDNA is detected an average of 5.5 months before radiographic progression.